Entera Bio Reports Full Year 2024 Financial Performance and Business Developments

Friday 28th of March 2025 20:05:00

Entera Bio Announces Full-Year 2024 Financial Results and Provides Business Updates

March 28, 2025 - WALTHAM, Mass. - Entera Bio, a biopharmaceutical company developing orally administered, peptide-based therapeutics for rare and serious diseases, today announced its full-year 2024 financial results and provided business updates.

Full-Year 2024 Financial Results:

  • Revenue: $1.2 million, primarily from collaboration agreements and grants
  • Net Loss: $23.4 million, or $0.44 per share
  • Research and Development (R&D) Expenses: $14.5 million
  • General and Administrative (G&A) Expenses: $4.4 million
  • Cash and Cash Equivalents: $15.1 million as of December 31, 2024

Key Business Updates:

  • The company's lead product candidate, efruxiostat, is a novel, orally administered, peptide-based therapeutic for the treatment of hypoparathyroidism, a rare endocrine disorder. Entera Bio plans to initiate a Phase 3 clinical trial for efruxiostat in the second half of 2025.
  • The company is also developing EN123-6, an orally administered, peptide-based therapeutic for the treatment of Fabry disease, a rare lysosomal storage disorder. Entera Bio plans to initiate a Phase 1 clinical trial for EN123-6 in the first half of 2025.
  • Entera Bio has strengthened its leadership team with the appointment of Dr. Rajan Kumar as Chief Medical Officer. Dr. Kumar brings over 20 years of experience in the biopharmaceutical industry, including leadership roles at companies such as Biogen and Pfizer.
  • The company has also expanded its scientific advisory board with the addition of Dr. David Ginsburg, a renowned expert in the field of rare diseases. Dr. Ginsburg is a professor of pediatrics and genetics at the University of Pennsylvania Perelman School of Medicine.

"We are pleased to announce our full-year 2024 financial results, which reflect our continued focus on advancing our pipeline of orally administered, peptide-based therapeutics for rare and serious diseases," said Jeffrey P. Miller, President and CEO of Entera Bio. "We are excited about the progress we have made in 2024 and look forward to continuing to execute on our strategic plan in 2025 and beyond."

About Entera Bio

Entera Bio is a biopharmaceutical company developing orally administered, peptide-based therapeutics for rare and serious diseases. The company's lead product candidate, efruxiostat, is a novel, orally administered, peptide-based therapeutic for the treatment of hypoparathyroidism, a rare endocrine disorder. Entera Bio is also developing EN123-6, an orally administered, peptide-based therapeutic for the treatment of Fabry disease, a rare lysosomal storage disorder. For more information, please visit our website at www.enterabio.com.